Mylan NV (MYL)

MYL (NASDAQ:Drugs) EQUITY
$42.06
pos +0.00
+0.00%
Today's Range: 41.95 - 42.69 | MYL Avg Daily Volume: 5,699,800
Last Update: 09/23/16 - 4:00 PM EDT
Volume: 0
YTD Performance: -22.21%
Open: $0.00
Previous Close: $42.59
52 Week Range: $37.59 - $55.51
Oustanding Shares: 534,911,497
Market Cap: 22,781,880,657
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 5 5
Moderate Buy 0 0 0 0
Hold 6 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.33 2.25 2.00 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.54%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 26.62
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
26.62 25.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-8.88% -7.38% 10.48%
GROWTH 12 Mo 3 Yr CAGR
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
EBITDA 2.40B
Revenue 9.43B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.59 $1.43 $4.93 $5.71
Number of Analysts 7 6 8 8
High Estimate $1.66 $1.48 $5.05 $6.00
Low Estimate $1.53 $1.33 $4.81 $5.44
Prior Year $1.43 $1.22 $4.30 $4.93
Growth Rate (Year over Year) 11.09% 17.21% 14.77% 15.73%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | Sep 23, 2016 | 11:29 AM EDT
The bear is in control.
RMPIA
By

Jim Cramer

 | Sep 22, 2016 | 3:25 PM EDT
And what happened to all those predicting a surprise rate hike?
By

Anders Keitz

 | Sep 21, 2016 | 8:20 AM EDT
Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
By

James Passeri

 | Sep 20, 2016 | 11:30 AM EDT
It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.
By

Tony Owusu

 | Sep 14, 2016 | 8:30 AM EDT
Bayer has agreed to purchase Monsanto for $66 billion, or $128 a share, a 20% premium over its previous closing price.
RMPIA
By

Bret Jensen

 | Sep 13, 2016 | 12:00 PM EDT
These stocks look good as seasonal volatility sets in.
RMPIA
By

Jim Cramer

 | Sep 13, 2016 | 7:05 AM EDT
Without it, the uncertainty would be incredible between now and November.
By

James Passeri

 | Sep 12, 2016 | 8:50 AM EDT
Falling crude oil prices continued to weigh on markets Monday.
By

Chris Laudani

 | Sep 6, 2016 | 10:00 AM EDT
The EpiPen controversy makes this stock a shot in the dark.

bearishMylan estimates, target cut at RBC

Sep 6, 2016 | 7:24 AM EDT
Shares of MYL now seen reaching $48, according to RBC Capital. Estimates also reduced, given lower Epipen price expectations. Sector Perform rating.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.